Abivax has treated the first patient in its Phase 2b/3 study of ABX464 in COVID-19 patients at the University Hospital Center in Nice, France (CHU Nice) in a randomized, double-blind, placebo-controlled study, to see the the effects of early treatment in 1034 Covid-19 older or high-risk patients.
EUSA Pharma gets FDA’s green light for further testing of siltuximab in COVID-19 patients with acute respiratory distress syndrome
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, received the approval from the U.S. Food & Drug Administration (FDA) for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to test intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the European Commission has granted marketing authorization for MVABEA® (MVA-BN Filo) together with ZABDENO® (Ad26.ZEBOV), which collectively constitute Janssen’s Ebola vaccine regimen. The approval follows a Positive Opinion by the CHMP of the European Medicines Agency (EMA) in May 2020.
BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma, a global leader in medical dermatology, today announced that Dr. Monica Shaw, M.D., and Nathalie Joannes
As Vertex expands deal with NHS England to include Kaftrio in combination with Kalydeco, the cysitc fibrosis patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the European Commission.
Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, continued its growth in 2019, recording a positive trend on key financial indicators, with consolidated revenues of €570.3 million, an increase of +10.9% compared to 2018.
Mereo BioPharma has named several new positions this week, thus reaffirming it’s management team with those appointments.
Roche Diabetes Care France, a healthcare company specializing in diabetes, will distribute Mallya to pharmacies in France to pharmacists and will integrate it into its Roche Diabetes digital ecosystem.
Freeline has closed a $120 million Series C financing, expecting to use the cash – among other plans – to bring its lead program in Haemophilia B into a pivotal trial. It was supported by leading international investors led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company.
Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A
Roche has announced updated from its combined haemophilia A programme, the data which exemplify the company’s efforts to increase its knowledge and capabilities in haemophilia A.